Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of recommended footwear fit upon in-shoe pressures in feet with diabetes-An exploratory study.

Diabetic medicine : a journal of the British Diabetic Association·2026

Same author

Effectiveness of tobacco cessation interventions delivered in clinical settings in South Asia: a systematic review and meta-analysis.

Global health action·2026

Same author

How Many Veteran COVID-19 Cases Were There during the Pandemic?

Journal of medical virology·2026

Same author

The Impact of the Multidisciplinary Team on Medication Adherence in Type 2 Diabetes: A Narrative Review.

Journal of multidisciplinary healthcare·2026

Same author

Comparative predictive accuracy of machine learning versus traditional statistical methods for diabetes-related complications: A systematic review and analysis.

Diabetic medicine : a journal of the British Diabetic Association·2026

Same author

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data.

Health technology assessment (Winchester, England)·2026

Search research articles

Related Experiment Video

Updated: May 19, 2026

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.

Jirawan Vienghirun¹, Ratree Sawangjit^2,3, Saithip Suttiruksa^2,3

¹Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.

Diabetes, Obesity & Metabolism

|March 24, 2026

Summary

Tirzepatide and subcutaneous semaglutide (Semaglutide_SC) are most effective for significant weight loss in adults with obesity. Optimal dosing and adherence are key for successful outcomes in clinical practice.

Keywords:

GLP‐1 receptor/dual agonists (GLP‐1RAs)non‐T2DM obesity semaglutide tirzepatide weight loss

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 19, 2026

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

Metabolic Disorders and Endocrinology
Pharmacology and Therapeutics
Clinical Trial Analysis

Background:

Obesity and Type 2 Diabetes Mellitus (T2DM) are significant global health challenges.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective therapeutic options for weight management.
Comparative efficacy of different GLP-1RAs requires robust evidence synthesis.

Conclusions:

Tirzepatide and Semaglutide_SC are the most effective agents for achieving clinically meaningful weight loss.
Individualized treatment approaches considering efficacy and tolerability are recommended.
Further research on optimal dosing strategies and patient adherence is warranted.